Precision medicine: affording the successes of science

Science has made remarkable advances in understanding the molecular basis of disease, generating new and effective rationally-designed treatments at an accelerating rate. Ironically, the successes of science is creating a crisis in the affordability of equitable health care. The COVID-19 pandemic un...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:NPJ precision oncology Ročník 7; číslo 1; s. 3 - 8
Hlavní autoři: Lu, Christine Y., Terry, Vera, Thomas, David M.
Médium: Journal Article
Jazyk:angličtina
Vydáno: London Nature Publishing Group UK 04.01.2023
Nature Publishing Group
Nature Portfolio
Témata:
692/308/153
692/4017
Biomarkers
Cancer Research
Drug development
Gene Therapy
Human Genetics
Internal Medicine
Medical research
Medicine
Medicine & Public Health
Oncology
Perspective
Pharmaceutical industry
Precision medicine
Targeted cancer therapy
ISSN:2397-768X, 2397-768X
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Science has made remarkable advances in understanding the molecular basis of disease, generating new and effective rationally-designed treatments at an accelerating rate. Ironically, the successes of science is creating a crisis in the affordability of equitable health care. The COVID-19 pandemic underscores both the value of science in health care, and the apparently inevitable tension between health and the economy. Drug development in ever-smaller target populations is a critical component of the rising costs of care. For structural and historical reasons, drug development is inefficient and poorly integrated across the public and private sectors. We postulate an alternative, integrated model in which governments and industry share the risks and benefits of drug development. The Australian government recently announced support for a AU$185 million innovative multi-stakeholder public-private partnership model for sustainable precision oncology, accelerating biomarker-dependent drug development through integrating clinical trials into the standard of care.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2397-768X
2397-768X
DOI:10.1038/s41698-022-00343-y